Powrót pełnej ostrości wzroku jako główny cel leczenia pacjentów z neuropatią nerwu wzrokowego w przebiegu orbitopatii Gravesa by Miśkiewicz, Piotr et al.
166
Prace oryginalne/original PaPers
Endokrynologia Polska
DOI: 10.5603/EP.a2016.0018
Tom/Volume 67; Numer/Number 2/2016
ISSN 0423–104X
Piotr Miskiewicz M.D., Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Żwirki i Wigury Str. 61, 
02–091 Warsaw, Poland, e-mail: pmiskiewicz@wum.edu.pl
Complete recovery of visual acuity as the main goal of 
treatment in patients with dysthyroid optic neuropathy
Powrót pełnej ostrości wzroku jako główny cel leczenia pacjentów z neuropatią 
nerwu wzrokowego w przebiegu orbitopatii Gravesa
Piotr Miśkiewicz1, Beata Rutkowska1, Anna Jabłońska2, Antoni Krzeski3, Katarzyna Trautsolt-Jeziorska1, 
Dariusz Kęcik2, Justyna Milczarek-Banach1, Katarzyna Pirko-Kotela1, Agnieszka Samsel2, Tomasz Bednarczuk1
1Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Poland 
2Department of Ophthalmology, Medical University of Warsaw, Poland 
3Department of Otolaryngology, Division of Dentistry, First Faculty of Medicine, Medical University of Warsaw, Poland
Abstract
Introduction: To evaluate the effectiveness of methylprednisolone (MP) and surgical treatment in achieving complete reversal of dysthy-
roid optic neuropathy (DON) and predictive factors of this therapy.
Material and methods: The group consisted of 10 patients (18 eyes) with DON. The diagnosis of DON was based on at least two criteria 
from the following: (i) deterioration of visual acuity (VA < 1.0), (ii) loss of colour vision, (iii) optic disc swelling, and/or (iv) signs of DON 
in magnetic resonance imaging (presence of apical crowding and/or optic nerve stretching). A complete recovery of DON was defined 
as the normalisation of VA (VA = 1.0), normal colour vision, and reversal of optic disc swelling. A significant improvement was defined 
as improvement of VA of at least 0.2. The consecutive steps of treatment of DON consisted of: (i) first-line treatment — intravenous MP 
pulse therapy (3 × 1 g); (ii) second-line treatment — endoscopic intranasal orbital decompression of medial wall; (iii) additional treat-
ment — additional MP therapy and/or surgical decompression.
Results: A significant improvement in VA could be achieved in the majority of patients; a complete recovery was noted in 22.2%, 33.3%, 
and 66.7% of eyes after first-line, second-line, and additional treatment, respectively. Positive predictive factors were: younger age 
(p = 0.049), shorter duration of DON (p = 0.035), and a higher Graves’ orbitopathy clinical activity score (p = 0.035).
Conclusions: By using combination therapy (intravenous MP pulse therapy and surgical decompression), a complete recovery can be 
achieved in the majority of patients with DON. (Endokrynol Pol 2016; 67 (2): 166–173)
Key words: dysthyroid optic neuropathy; Graves’ orbitopathy; Graves’ disease; orbital decompression; methylprednisolone; endoscopic 
intranasal orbital decompression
Streszczenie
Wstęp: Celem badania była ocena skuteczności leczenia metyloprednizolonem (MP) i leczenia chirurgicznego w uzyskaniu ustąpienia 
klinicznych cech neuropatii nerwu wzrokowego w przebiegu orbitopatii Gravesa (DON) oraz wskazanie czynników prognostycznych 
skuteczności terapii DON.
Materiał i metody: Grupę badaną stanowiło 10 pacjentów (18 gałek ocznych) z DON. Rozpoznanie DON było stawiane na podstawie 
spełnienia co najmniej dwóch kryteriów z powyższych: a) pogorszenie ostrości wzroku (VA < 1,0), b) pogorszenie widzenia kolorów, 
c) obrzęk tarczy nerwu wzrokowego i/lub d) obraz typowy dla DON w badaniu rezonansu magnetycznego (stłoczenie w szczycie oczodołu 
i/lub naprężenie nerwu wzrokowego). Jako pełną poprawę uznano normalizację VA (VA = 1,0), prawidłowe widzenie barw i brak obrzę-
ku tarczy nerwu wzrokowego. Kolejnymi etapami leczenia DON były: a) leczenie pierwszoplanowe — pulsy MP (3 × 1 g); b) leczenie 
drugoplanowe — endoskopowa wewnątrznosowa dekompresja ściany przyśrodkowej oczodołu; c) leczenie dodatkowe — podanie 
dodatkowych pulsów MP i/lub chirurgiczna dekompresja.
Wyniki: Znaczącą poprawę VA uzyskano u większości pacjentów. Pełną poprawę stwierdzono w 22,2%, 33,3% i 66,7% gałek ocznych 
odpowiednio po leczeniu: pierwszoplanowym, drugoplanowym i dodatkowym. Czynnikami pozytywnie korelującymi z osiągnięciem 
pełnej poprawy były: młodszy wiek (p = 0,049), krótszy czas trwania DON (p = 0,035), wyższa aktywność kliniczna orbitopatii Gravesa 
(p = 0,035).
Wnioski: Zastosowanie złożonej terapii (pulsy MP i chirurgiczna dekompresja) umożliwia osiągnięcie pełnej poprawy u większości 
pacjentów z DON. (Endokrynol Pol 2016; 67 (2): 166–173)
Słowa kluczowe: neuropatia nerwu wzrokowego; orbitopatia Graves’a; choroba Gravesa i Basedowa; dekompresja; metyloprednizolon; 
endoskopowa wewnątrznosowa dekompresja oczodołu
Abbreviations
CAS — clinical activity score
DON — dysthyroid optic neuropathy
EUGOGO — European Group on Graves’ Orbitopathy
EIODM — endoscopic intranasal orbital decompression 
of medial wall
GO — Graves’ orbitopathy
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ivMP — intravenous methylprednisolone pulse therapy 
ivGCS — intravenous glycocorticosteroid pulse therapy 
MP — methylprednisolone
MR — magnetic resonance 
TBII — TSH binding inhibitory immunoglobulin
VA — visual acuity
Introduction
Dysthyroid optic neuropathy (DON) is a sight-threatening 
complication that occurs in approximately 5% of patients 
with Graves’ orbitopathy (GO) [1]. The pathomechanisms 
of GO are inflammation, adipogenesis, and the produc-
tion of glycosaminoglycans, which lead to an enlargement 
of eye muscles and expansion of the orbital connective 
tissue [2]. DON can be a result of optic nerve compres-
sion by swollen muscles and fat in the orbital apex [3, 4]; 
however, an ischaemic mechanism or optic neuritis is 
also considered [5]. There is no defined “gold standard” 
for diagnosis and management of DON. The European 
Group on Graves’ Orbitopathy (EUGOGO) recommends 
intravenous glycocorticosteroid pulse therapy (ivGCS) 
and urgent decompression if there is no response for two 
weeks [6, 7]. Decompression of the medial orbital wall is 
the optimal surgical strategy [8]. However, there are no 
recommendations on how aggressive further therapy 
should be in cases where a complete recovery is not 
achieved. We believe that any worsening of visual acuity 
(VA) may be life-disturbing. Therefore, we decided to 
continue additional therapy to try to achieve a complete 
recovery (normalisation of VA, normal colour vision, and 
a normal-appearing optic disc) if ivGCS treatment and 
orbital decompression of the medial wall were insufficient. 
The first aim of our study was to assess the effective-
ness of combined ivGCS and orbital decompression in 
achieving a complete recovery of DON. The second 
aim was to define the predictive factors of this therapy.
Material and methods
Patients
The study was conducted at an academic referral centre. 
Patients with DON were consecutively recruited from 
the Department of Endocrinology, Medical University 
of Warsaw from 2009 to 2014. The inclusion criterion 
was a diagnosis of DON based on at least two signs, 
including (i) deterioration of VA (< 1.0), (ii) loss of colour 
vision (more than three errors in Ishihara plates), (iii) 
optic disc swelling, and/or (iv) signs of DON in a mag-
netic resonance (MR) scan (presence of apical crowding 
and/or optic nerve stretching). Exclusion criteria were: 
(i) other diseases that affect visual function, such as 
glaucoma, cataract, high myopia, or corneal exposition, 
and (ii) orbital decompression in the past. Ten patients 
(a total number of 18 eyes) were eligible for the study. 
The clinical characteristics of the analysed group are 
shown in Table I. 
Ophthalmological and radiological examination
All the patients were assessed according to EUGOGO 
criteria. A clinical activity score (CAS) including two 
symptoms (orbital ache and gaze-evoked pain) and five 
signs (conjunctival redness, eyelid erythema or oedema, 
chemosis, and swelling of the plica or caruncle) for each 
eye was evaluated. GO was assessed as active if CAS was 
≥ 3/7. Proptosis was measured with a Hertel exophthal-
mometer. Colour vision was tested using Ishihara plates. 
VA was examined using Snellen charts and expressed 
as a decimal fraction. The ophthalmologic examination 
also included assessing the fundus and intraocular 
pressure. The Gorman score (no diplopia, intermittent 
diplopia, inconstant diplopia, and constant diplopia) 
was used to assess the severity of diplopia. All the 
ophthalmologist examinations for the all patients were 
carried out by the same ophthalmologist. The baseline 
ophthalmological and radiological characteristics of the 
analysed group are shown in Table II. 
Laboratory evaluations
Thyroid-stimulating hormone (TSH), free triiodothyro-
nine, free thyroxine as well as TSH binding inhibitory 
immunoglobulin (TBII), thyroid peroxidase antibod-
ies, and thyroglobulin antibodies concentrations were 
Table I. Characteristic of patients with DON (n = 10)
Tabela I. Charakterystyka pacjentów z DON (n = 10)
Number of patients/mean
Graves’ Disease 8
Hashimoto Disease 2
Female 9
Age 56 (range: 31 to 76)
Active Smokers 5
Duration of thyroid disease in weeks 170 (range: 17 to 806)
Duration of GO in weeks 29 (range: 20 to 806)
Duration of symptoms of DON in weeks 10 (range: 3 to 127)
Previous treatment with GCS 6
TSH (reference range:  
0.270–4.200 µIU/mL)
0.45 (range: 0.005 to 2.96)
fT3 (reference range: 3.1–6.8 pmol/L) 4.93 (range: 3.88 to 12.95)
fT4 (reference range: 12–22 pmol/L) 17.43 (range: 12.3 to 23.21)
TBII (reference range: < 1.75 IU/L) 21.6 (range: 0.1 to 40)
DON — dysthyroid optic neuropathy; GO — Graves’ Orbitopathy; GCS 
– glicocorticosteroids; TSH — thyroid-stimulating hormone; fT3 — free 
triiodothyronine, fT4 — free thyroxine; TBII — TSH binding inhibitory 
immunoglobulins
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measured using an electro-chemiluminescence im-
munoassay performed on a Cobas 6000 analyser from 
Roche Diagnostics (Mannheim, Germany).
Treatment schedule
The treatment schedule is shown in Figure 1. The con-
secutive steps of treatment of DON consisted of: 
 — first-line treatment - intravenous methylpredniso-
lone (ivMP) pulse therapy (3 × 1.0 g given on three 
consecutive days); 
 — second-line treatment - endoscopic intranasal orbital 
decompression of medial wall (EIODM). EIODM 
was performed endonasally, employing an opera-
tive endoscopic technique described by Kennedy 
in 1990 [9]. After endonasal sphenoethmoidectomy, 
the orbital wall was resected to reveal the periorbit. 
Then a longitudinal cut of the periorbit was carried 
out, which allowed the adipose tissue of the orbit to 
fill the space of the former ethmoidal cells;
 — additional treatment, which consisted of additional 
ivMP pulse therapy, additional orbital decompres-
sion (lateral, inferior or medial wall), or combined 
ivMP therapy and decompression. The decision 
about additional therapy was made individually for 
each patient by an endocrinologist, ophthalmologist, 
and laryngologist on the basis of the following fac-
tors: the degree of proptosis, MR findings after EI-
ODM, and the effect of the first ivMP pulse therapy. 
Patients with a complete recovery after the first- 
and second-line treatment were further treated with 
12 pulses of ivMP in every week schedule (a cumulative 
dose of 4.5 g) tapered off with prednisone (a cumulative 
dose of 1.8 g). Patients with active GO (CAS ≥ 3) and 
impairment of ocular movement after the 12 pulses 
of ivMP were referred for retrobulbar radiotherapy. 
A cumulative dose of 20 Gy per orbit fractioned in 
10 doses over a two-week period according to EUGOGO 
recommendations was adopted [6]. This therapy was 
conducted with concomitant prednisone administration.
Subjects with hyperthyroidism were treated with 
a combined therapy (an antithyroid drug and thyroxine) 
and those with hypothyroidism received L-thyroxine. 
All but one were euthyroid when DON treatment was 
initiated. 
Before each ivMP pulse, a careful clinical examina-
tion (including symptoms/ signs of coronary artery 
disease, infections, psychiatric disorders, and high 
blood pressure) and lab tests were performed (including 
serum potassium, glucose concentration, AST and ALT 
activity, and urine analysis). All possible side effects of 
GCS therapy and orbital decompression were recorded. 
Outcome analysis
Complete recovery of DON was defined as normalisa-
tion of VA, normal colour vision, and a normal-appear-
ing optic disc. Significant improvement was defined as 
final VA: + 0.2 in comparison to the baseline; stabilisa-
tion as final VA: ± 0.1 in comparison to the baseline, 
and deterioration as a worsening of VA of at least 0.2.
An ophthalmological examination with an assess-
ment of VA, colour vision, and optic fundus was per-
formed: before therapy (a baseline assessment), after 
first-line treatment with 3 g of ivMP, after second-line 
treatment - EIODM, after additional therapy, and after 
completing the whole therapy (Fig. 1). 
Additionally, we analysed whether specific factors, 
such as baseline clinical and radiological signs of DON, 
CAS, age, smoking, TBII concentration, duration of GO, 
and symptoms of DON, are associated with a complete 
recovery after therapy. 
Statistical analysis
Median values (range: minimum value–maximum 
value) were used to present continuous variables, 
while categorical variables were expressed as numbers 
or percentage values. Comparisons of the continuous 
data were performed with the nonparametric unpaired 
Mann-Whitney U test. A Chi-squared test was used to 
analyse the differences in the categorical data. Statistical 
Table II. Baseline ophthalmological and radiological 
characteristic of eyes affected with DON (n = 18)
Tabela II. Wyjściowa ocena gałek ocznych z cechami DON w 
badaniu okulistycznym i radiologicznym (n = 18)
Numbers  
of eyes/mean
% of  
all eyes
Apical crowding 9 50%
Optic nerve stretching 15 83%
Reduction of VA 18 100%
VA = 0.8 4
VA = 0.7 2
VA = 0.6 3
VA = 0.5 5
VA = 0.4 2
VA = 0.3 1
VA = 0.2 1
Impaired colour sensitivity 3 17%
Optic disc swelling 3 17%
CAS 4 (range 2–6)
Proptosis [mm] 21 (range 16–26)
Diplopia in Gorman score:
none/intermittent/inconstant/constant 2/0/2/4
DON — dysthyroid optic neuropathy; VA — visual acuity; CAS — clinical 
activity score
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significance was established for results using a p value 
of < 0.05. All analyses were made with the statistical 
software STATISTICA ver.10.0.
Results
Effectiveness of therapy
A complete recovery was noted in 22.2%, 33.3%, and 
66.7% of eyes after first-line, second-line, and additional 
treatment, respectively (Fig. 2). VA, colour vision, and 
optic fundus findings remained stable during further 
therapy. 
At the end of the therapy, all patients had normal 
colour vision and normal-appearing optic discs. The 
median of VA increased from 0.55 (range from 0.2 to 
0.8) to 1.0 (range from 0.7 to 1.0); in 12 out of the 
18 eyes VA was normalised (VA = 1.0); in four significant 
improvement was achieved; and in two VA remained 
Figure 1. Schedule of treatment of dysthyroid optic neuropathy
Rycina 1. Schemat zastosowanego leczenia neuropatii nerwów wzrokowych
*without any clinical sings of DON, † additional treatment consisted of: a second decompression (one eye — decompression of lateral and 
inferior wall; 2 eyes — decompression of medial wall) and/or additional MP pulse therapy. ivMP — intravenous methylprednisolone; 
EIODM — endoscopic intranasal orbital decompression of medial wall
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stable. Of these patients, one discontinued therapy af-
ter second-line treatment, having achieved significant 
improvement in one eye and stabilisation in the second. 
At the end of therapy, the median CAS decreased from 
4 (range from 3 to 6) to 2 (range from 0 to 3). Proptosis 
decreased from 21 (range from 16 to 26) to 20 (range 
from 15 to 25). Diplopia in primary gaze was noticed in 
seven patients (two new cases after EIODM). 
Four patients (eight eyes) with active GO and eye 
muscle dysfunction at the end of therapy were referred 
for retrobulbar radiotherapy, which effected a decrease 
in CAS. Patients with constant diplopia were referred 
for anti-squint surgery when their GO was inactive and 
stable for at least six months.
Analysis in subgroups
The analysis in subgroups with and without complete 
recovery after the end of the therapy (evaluation after 
additional treatment — Fig. 1) is shown in Table III. 
Patients with a complete recovery were significantly 
younger than those in the subgroup without complete 
recovery (53 vs. 68 years, respectively, p = 0.049), had 
a shorter duration of DON (8.4 vs. 29.7 weeks, respec-
tively, p = 0.035), and had a higher GO activity (CAS 
4 vs. 3, respectively, p = 0.035). 
Side effects
The mean cumulative dose of ivMP was 7.5 g (range 
3.0 to 16.5 g); two patients received doses exceeding 
Figure 2. Schedule of treatment with the number of eyes with: complete recovery, significant improvement, stabilization and deterioration 
after ivMP, after EIODM and after additional treatment
Rycina 2. Schemat leczenia oraz liczba gałek ocznych z całkowitą poprawą, znaczącą poprawą, stabilizacją oraz pogorszeniem u chorych 
po leczeniu ivMP, po wykonaniu EIODM oraz po zastosowaniu dodatkowego leczenia
*additional treatment consisted of: a second decompression (one eye — decompression of lateral and inferior wall; 2 eyes — decompression 
of medial wall) and/or additional MP pulse therapy. ivMP — intravenous methylprednisolone; EIODM — endoscopic intranasal orbital 
decompression  of medial wall
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8.0 g (one — 9.3 g, the other — 16.5 g). After ivMP, we 
observed only mild and temporary side effects, such 
as insomnia (n = 1), dyspepsia (n = 1), facial flushing 
(n = 2), or harmless cardiac arrhythmias in the form of 
a single supraventricular extrasystole (n = 1). In one 
patient an increase of intraocular pressure was diag-
nosed and normalised successfully with antiglaucoma 
drops. We did not observe a significant (i.e. a fourfold) 
increase in transaminase activity after ivMP. 
After EIODM recurrent sinusitis occurred in one 
patient. Additionally, a new onset of diplopia in the 
primary gaze was noticed in two patients: one without 
diplopia before treatment and the second with incon-
stant diplopia before treatment. 
Discussion 
DON is a fairly rare medical problem, the diagnosis and 
treatment of which still remain a dilemma. Lower social 
class, higher social deprivation, smoking, and older age 
are factors associated with more severe types of GO, in-
cluding DON [10–12]. It is worth emphasising that there 
is no pathognomonic feature of DON. Distinguishing 
DON from other causes of ophthalmological deterio-
ration (e.g. cataract, corneal damage) can be difficult 
and is often delayed. Lack of appropriate treatment of 
DON may cause further worsening of ophthalmological 
complications and blindness. There have been no stud-
ies addressing the problem of how aggressive therapy 
should be in order to achieve a complete recovery. 
Clinical factors that predict a better outcome of DON 
treatment, and in particular a complete recovery, are 
largely unknown.
The diagnostic criteria of DON are not clearly de-
fined. McKeag indicates impairment of colour vision 
and optic disc swelling together with radiological evi-
dence of apical optic nerve compression, as frequently 
used for DON diagnosis [13]. Most authors suggest di-
agnosing DON on the basis of a combination of clinical 
and radiological features. However, at least one feature 
is obligatory (Curro et al. — at least one feature of DON 
in MR and at least two in ophthalmological examina-
tion, Mourits et al. — obligatory apical crowding in 
CT; Wakelkamp et al. — obligatory deterioration of VA 
< 0.67) [7, 14, 15]. We diagnosed DON if a patient fulfilled 
at least two of the following criteria: deterioration of 
VA and/or loss of colour vision and/or optic disc swell-
ing and/or signs of DON in MR. The most common 
symptoms in our patients were optic nerve stretching 
(83%) and reduction of VA (100%). 
The schedule of glucocorticoid treatment of DON 
is also vague. Wakelkamp et al. confirmed ivMP as 
an effective first-line treatment [7]. EUGOGO recom-
mends initial therapy with ivGCs and urgent surgical 
decompression if the response is poor after one to two 
weeks [6, 7]. Curro et al. administered either 0.5 or 1.0 
g of ivMP daily for three consecutive days, repeated 
after one week and followed with a tapering dose of 
steroids either orally or intravenously [14]. Hart et al. 
administered ivMP in three consecutive daily doses of 
Table III. Comparison of selected data of patients with DON with and without complete recovery at the end of the therapy
Tabela III. Porównanie wybranych danych chorych oraz cech gałek ocznych z DON u chorych z całkowitą poprawą i bez 
poprawy po całkowitym leczeniu
Complete recovery Without complete recovery P value
Apical crowding (n) 6 3 1.00*
Optic nerve stretching (n) 11 4 0.18*
Baseline VA (decimal fraction) 0.6 0.5 0.96**
Impaired colour sensitivity (n) 2 1 0.87*
Optic disc swelling (n) 3 0 0.18*
CAS 4 3 0.035**
Proptosis [mm] 21 21 0.74**
Age (years) 53 68.5 0.049**
Smokers (n) 6 3 1.00*
TSH (reference range 0.270–4.200 µIU/mL) 0.45 1.04 0.45**
TBII (reference range < 1.75 IU/L) 24.69 17.95 0.22**
Duration of GO (weeks) 25 416 0.20**
Duration of symptoms of DON (weeks) 8.4 29.7 0.035**
DON — dysthyroid optic neuropathy; VA — visual acuity; CAS — clinical activity score; TSH — thyroid-stimulating hormone; TBII — TSH binding inhibitory 
immunoglobulins; GO — Graves’ Orbitopathy. Values are presented as median or otherwise as indicated;  *chi-squared test; **nonparametric unpaired Mann-Whitney 
U test
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0.5 g and followed with oral prednisone [16]. Mourits 
et al. administered four single pulses of 0.5 g of ivMP 
every second day, tapered off with oral prednisone 
[15]. Guy et al. administered 1.0 g of ivMP divided 
into four daily doses of 0.250 g administered every 
six hours for three consecutive days [17]. There is still 
a lack of recommendations concerning patients without 
improvement after initial therapy. In such cases further 
therapy should be individualised.
We used pulses with 1.0 g of ivMP, given for three 
consecutive days. Then patients with a complete reco-
very were treated with 12 pulses of ivMP given once 
a week and prednisone in tapering doses. EIODM was 
performed in patients without complete improvement 
after therapy with 3.0 g of ivMP. This schedule of first- 
and second-line treatment enables a reduction of the 
cumulative doses of ivMP to less than 8.0 g with an op-
portunity for prolonged immunosuppressive therapy 
and stabilisation of VA during the follow-up. Exceeding 
the cumulative dose of over 8.0 g is associated with an 
increased risk of fatal side effects [6, 18]. However, two 
patients without a complete recovery after first- and 
second-line treatment received cumulative doses of 
over 8.0 g. No severe side effects were observed during 
a careful follow-up.
Different approaches to orbital decompression for 
DON are also described. Many authors recommend 
decompression of the medial wall as the best approach 
for patients with DON [8, 9, 19]. However, other surgical 
approaches are also presented: two-wall medial-lateral 
and three-wall medial-lateral-inferior orbital decom-
pression combined with fat removal [20]. Due to such 
advantages as good visualisation of the orbital apex, 
the short time of hospitalisation, and lack of external 
scars, we performed EIODM. A new onset of diplopia 
in the primary gaze after EIODM was observed in two 
of the four patients without constant diplopia. Apart 
from a new onset of diplopia and recurrent sinusitis in 
one patient, we did not observe any other side effects 
resulting from this procedure. In patients with DON, 
ineffective ivMP pulse therapy, rituximab may be used. 
Unfortunately, this drug is not registered for GO treat-
ment and we were unable to use it.
The criteria of improvement of DON are differently 
defined (Curro et al. — VA > 0.8 with normal visual 
fields and colour vision, Wakelkamp et al. — VA > 0.63 
and no signs of DON, Mourits et al. — VA > 0.5 and 
improved or normal visual fields and colour vision, 
Hart et al. — the improvement in VA by two lines in 
the Snellen chart in the worst-affected eye) [7, 14–16]. 
However, even mild VA impairment could potentially 
deteriorate the health-related quality of life [21]. It was 
also confirmed in patients with GO that vision-related 
quality of life tended to be more severely impaired 
in patients with DON than in patients without DON 
[22]. We believe that any worsening of VA may be life-
disturbing. Therefore, if a patient had any impairment 
of VA with no other concomitant eye disease, we tried 
to achieve normalisation of VA. If baseline therapy was 
ineffective, additional procedures were introduced ac-
cording to individual considerations. 
As mentioned above, in literature various criteria 
of improvement after treatment of DON are used, so 
comparison of treatment schedules are difficult. First-
line treatment with ivMP was efficient in about 50% of 
eyes in the mentioned studies (Wakelkamp et al. — 55%, 
Mourits et.al — 39%, Curro et al. — 42%) [7, 14, 15]. 
Mourits et al. have shown that improvement (described 
as VA > 0.5) was achieved in 83% of eyes (ivMP plus 
orbital decompression if necessary) [15]. In cases of 
insufficient improvement additional therapy should 
be introduced without delay. In a retrospective study 
performed by Soares-Welch, who evaluated the effi-
ciency of transantral orbital decompression (about half 
of the patients with preceding corticosteroid therapy), 
an improvement by ≥ 3 Snellen lines was observed in 
54% of eyes with VA ≤ 20/40 before decompression [23]. 
In a recent study evaluating an augmented endoscopic 
transethmoid medial orbital wall decompression with 
fat decompression 95.8% had a statistically significant 
improvement in VA (mean improvement of 0.55  ±  0.17) 
[19]. Our main therapeutic goal was the complete recov-
ery of VA including a reversal of other clinical symptoms 
of DON such as achieving normal colour vision and 
a normal-appearing optic disc. 
The results of our study support the strategy of com-
bination therapy (ivMP and surgical decompression), 
which can lead to a significant improvement in almost 
all the patients in the study and a complete recovery in 
the majority of eyes (about 70%). The lowest VA after 
completion of therapy was 0.7.
Based on further analysis, we found that the young-
er age of patients was a positive predictor of a complete 
recovery after full treatment. Patients with DON are 
older compared to patients with GO but without DON 
[12]. The average age of patients with DON is about 
55 years [15, 23, 24], which is similar to our results. An 
older age may be associated with adverse factors related 
to reconstruction in the muscles, which may affect the 
therapeutic efficacy. The treatment schedule in this 
group should probably be combined and divided into 
many steps to avoid serious side effects. Additionally, 
we found that a shorter duration of DON and higher 
activity score of GO are predictive factors of a complete 
recovery. The early phase of DON could be associated 
with a higher CAS and better outcome of treatment. 
Recognition during the later phase diminishes the 
effectiveness of therapy and often requires additional 
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treatment. It should focus our attention on the early 
recognition and treatment of DON. 
The main limitations of the study were the small 
number of patients and the retrospective analysis. 
However, the results of our study allow the following 
conclusions to be drawn. 
Conclusions
1. By using combination therapy (ivMP and surgical 
decompression), improvement can be achieved in 
almost all eyes with DON, with a complete recovery 
in the majority of cases. In many instances after first- 
and second-line treatments, an individual approach 
to patients with DON is needed.
2. Younger age, shorter duration of DON, and higher 
CAS are predictive factors of a complete recovery 
after combination therapy. 
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